Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
Phase 1
- Conditions
- COVID-19 PneumoniaCOVID-19Ventilator Associated PneumoniaCOVID-19 Acute Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT05258682
Nebulised BromAc in Healthy Volunteers
Phase 1
Completed
- Conditions
- Mucus; PlugCOVID-19 Acute Respiratory Distress SyndromeBromelains Adverse ReactionCOVID-19 PneumoniaAcetylcysteine Adverse Reaction
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05220605
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Phase 2
- Conditions
- Mucinous AdenocarcinomaPseudomyxoma PeritoneiPeritoneal CancerMucinous Tumor
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Mucpharm Pty Ltd
- Target Recruit Count
- 62
- Registration Number
- NCT03976973
News
No news found